Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19).


The COVID-19 pandemic is an urgent health emergency (as defined by the CDC and WHO). Innovative technologies to diagnose the virus and/or infection rapidly at the point of care setting, vaccines and other technologies to prevent and protect from infections, and therapeutics to treat the disease and manage symptoms are urgently needed.

The SBIR/STTR programs fund and support small businesses developing innovative technologies to improve health and well-being. There is an opportunity to adapt and retool a number of these innovative technologies that SBIR/STTR-funded small businesses are already developing to diagnose, prevent, and treat novel coronavirus and COVID-19. Through this NOSI, NCI encourages small businesses with NCI-funded active SBIR/STTR awards with promising technologies to submit applications to PA-18-935, Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).

Sponsor or Type
June 26, 2020

Subscribe to the UArizona Impact in Action newsletter to receive featured stories and event info to connect you with UArizona's research, innovation, entrepreneurial ventures, and societal impacts.

Subscribe now